AILERON Therapeutics is a biopharmaceutical company developing a breakthrough class of drugs called Stapled Peptides. This new class of drugs represents the first general solution for modulating intracellular protein-protein interactions, which have been identified as critical control points for most human diseases. Aileron's new therapeutic modality creates a unique opportunity to exploit potentially thousands of currently "undruggable" targets with applications in all human diseases.
